Clinical trials: Pandemic Response
Oncology, COVID-19
Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic
This registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of COVID-19 with the biological and clinical parameters in patients followed in Oncology during the COVID-19…
- Trial name
- OBVIONCO (NCT04437719)
- Testing
- Obvio-19 app
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Avian Influenza
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine
This study aim to compare immunogenicity of the inactivated H5 influenza vaccine single dose between subjects previously vaccinated with LAIV H5N2 and naïve subjects
- Trial name
- NCT02229357
- Testing
- OrniFlu® inactivated vaccine
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Coronavirus, Trust
Migrant Workers' Responses to the COVID-19 Pandemic
Rumors circulate widely during public health crises and have deleterious consequences. In this study, we seek to document the base rates of migrant workers' rumor exposure and identify predictors of rumor hearing, sharing and…
- Conditions
- Coronavirus, Trust, Misinformation
- Trial name
- NCT04718519
- Where
- Singapore
- Volunteers
- 1,011 people, healthy volunteers welcome
- Sponsor
- Yale-NUS College
Influenza, Virus Diseases
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)
Avian influenza (AI), also known as bird flu, has become a major public health concern in many regions of the world. The purpose of this study is to evaluate the safety of and immune response to an AI vaccine in healthy adults.
- Trial name
- NCT00380237
- Testing
- H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Virus Diseases
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of safe and effective vaccines against avian strains infecting people is important.
- Trial name
- NCT00516035
- Testing
- Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV-2
COVID-19 Pandemic Response Network
Coronavirus Disease 19 (COVID-19) represents an unprecedented challenge to the operations and population health management efforts of health care systems around the world.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus, Influenza -Like Illness
- Trial name
- NCT04320862
- Where
- United States
- Volunteers
- 9,207 people, healthy volunteers welcome
- Sponsor
- Duke University
Influenza, Virus Diseases
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
In the 20th century, influenza pandemics occurred in 1918, 1957, and 1968, and were associated with significant morbidity and mortality.
- Trial name
- NCT00734175
- Testing
- H6N1 Teal HK 97/AA ca recombinant vaccine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sedentary Behavior, Mental Health Wellness 1
Influence Physical Activity Psychological Responses COVID-19 Pandemic
The on-going Wuhan coronavirus (COVID-19) outbreak has become the world's leading health headline and is causing major panic and public concerns.
- Trial name
- NCT04352517
- Testing
- Online Survey
- Where
- 3 sites in Brazil, Chile and 1 more
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- University of Extremadura
Anxiety, Healthy Volunteers
Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses
Background: Researchers think that people s mental health and behavior will be very affected by the steps taken to slow the spread of COVID-19, such as social distancing.
- Trial name
- NCT04377100
- Testing
- Computer task questionnaires
- Where
- United States
- Volunteers
- 2,962 people
- Sponsor
- National Institute of Mental Health (NIMH)
SARS-CoV Infection, Covid19
The CHILD Cohort COVID-19 Add-On Study
The objective of this study is to determine the prevalence and transmission of SARS-CoV-2 infection among Canadian children and parents in the CHILD cohort, identify predictors of infection susceptibility and severity, and…
- Trial name
- NCT05234359
- Testing
- Serology Testing, Stool sample
- Where
- Canada
- Volunteers
- 5,385 people
- Sponsor
- University of Manitoba
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03022422
- Testing
- TIV, High-Dose TIV
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Stanford University
COVID-19, Vaccination
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
Background: Vaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these vaccines appear to wane over time.
- Conditions
- COVID-19, Vaccination, Healthy Volunteer
- Trial name
- NCT05078905
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Grippe, Influenza
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza.
- Conditions
- Grippe, Influenza, Vaccines
- Trial name
- NCT06179446
- Testing
- pdmFlu vaccine, Licensed influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Covid Vaccination in Liver Transplantation
The goal of this retrospective study is to evaluate the proportion of seroconversion after 2 doses mRNA anti-SARS-CoV2 vaccination in a cohort of high risk liver transplanted patients.
- Trial name
- VACCHEPA (NCT05079165)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03023176
- Testing
- Fluzone® standard IIV3, Fluzone® standard IIV3 Pediatric Dose
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza Prevention, Pandemic Influenza Prevention
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu.
- Trial name
- NCT07111078
- Testing
- VRC-FLUMOS0122-00-VP, ALFQ
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine
Rationale: Covid-19 spreads rapidly throughout the world. A large epidemic in the Netherlands would seriously challenge the available hospital capacity, and this would be augmented by absenteeism of healthcare workers (HCW).
- Trial name
- BCG-CORONA (NCT04328441)
- Testing
- BCG Vaccine
- Where
- 9 sites in Netherlands
- Volunteers
- 1,511 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht